

Claris undergoes USFDA Audit for Pharmacovigilance with No Observations

1st June, 2017. Ahmedabad, India: Claris Lifesciences Limited (CLL) along with its wholly owned subsidiary Claris Injectables Limited (CIL) announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from Monday 29th May to Wednesday 31st May with No Observation (i483s).

###

Disclaimer

This press release may include forward-looking statements; including but not limited to budget forecasts and projections; which involve a number of risks, uncertainties and other factors that may cause the actual results to differ materially. Such factors include; but are not limited to; change in local and global economic conditions our ability to successfully implement our strategy, the market acceptance of and demand of our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from the actual returns, in future. Claris Lifesciences Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Market information mentioned in the press release is based on IMS Data and/or internal estimates of the Company.

Claris Lifesciences Limited (CLL)

CLL is a multi-business enterprise and the Holding Company of Claris Injectables Limited, a wholly-owned subsidiary dealing in Specialty Injectables business and Claris Otsuka Private Limited, a Joint Venture with Japanese Otsuka Pharmaceutical Factory, Inc. & Mitsui & Co. Ltd. for Infusion business in India & Emerging Markets.

Claris Injectables Limited (CIL)

CIL manufactures and/or markets products across multiple delivery systems, markets, and therapeutic segments including anesthesia, blood products, anti-infectives, and plasma volume expanders. A significant majority of these products are generic drugs, capable of being directly injected into the human body, predominantly used in the treatment of critical illnesses.

The customer base primarily includes government & private hospitals, aid agencies, and nursing homes. With emphasis on quality, technology, and innovation, we offer a range of niche technology-driven injectable products across delivery systems such as glass bottles, vials & ampoules, and non-PVC/PVC bags.



K. K. K.

Claris Lifesciences Limited

Claris Corporate Headquarters, Nr. Parimal Rly. Crossing,
Ellisbridge, Ahmedabad 380 006, India.
Tel: +91-79-26563331, 66309339 Fax: +91-79-26408053
www.clarislifesciences.com

(Corporate Identity Number: L85110GJ1994PLC022543)

f /clarisltd | in /company/claris-lifesciences-limited